Brian Shinder, MD
Assistant ProfessorCards
About
Research
Publications
2024
Chapter 30 The emerging genetic landscape of renal cell carcinoma
Lee G, Shinder B, Sadimin E, Stephenson R, Singer E. Chapter 30 The emerging genetic landscape of renal cell carcinoma. 2024, 447-460. DOI: 10.1016/b978-0-12-822824-1.00035-3.ChaptersRenal cell carcinomaCell carcinomaOrgan-confined renal cell carcinomaKidney cancerMetastatic renal cell carcinomaLong-term survival outcomesLandscape of renal cell carcinomaDiagnosis of kidney cancerRenal tubule epithelial cellsTubule epithelial cellsGroup of diseasesSurgical resectionSystemic therapyDistant metastasisSurvival outcomesDiagnosed patientsEpithelial cellsPatientsPatient deathGenetic landscapeCarcinomaDiseaseCancerResectionMetastasis
2023
Predictive Biomarkers in Advanced Renal Cell Carcinoma
Shinder B, Kronstedt S, Hakimi A. Predictive Biomarkers in Advanced Renal Cell Carcinoma. 2023, 251-268. DOI: 10.1007/978-3-031-40901-1_11.ChaptersRenal cell carcinomaAdvanced renal cell carcinomaCell carcinomaPredictive biomarkersEra of treatment optionsCharacteristics of renal cell carcinomaPrediction of treatment responseOptimal therapeutic pathwayTargeted systemic therapyImmuno-oncology agentsRoutine clinical useSystemic therapyAdvanced diseaseClinical benefitTreatment responseTreatment optionsClinical useTherapeutic pathwaysCarcinomaPatientsBiomarkersMolecular characteristicsTherapyChromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation
Lichtbroun B, Shinder B, Sara T, Srivastava A, Saraiya B, Mayer T, Cristelli R, Sadimin E, Weiss R, Singer E. Chromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation. Journal Of Kidney Cancer And VHL 2023, 10: 1-8. PMID: 37441361, PMCID: PMC10334999, DOI: 10.15586/jkcvhl.v10i3.254.Peer-Reviewed Case Reports and Technical NotesChromophobe renal cell carcinomaSarcomatoid differentiationRenal cell carcinomaCell carcinomaClinical courseCases of ChRCCSystemic treatment optionsAggressive clinical courseMetastatic diseaseOverall survivalFavorable prognosisLarger tumorsClinicopathological dataPoor prognosisTreatment optionsPoor outcomeKidney cancerChRCCCarcinomaPrognosisDifferentiationSarcomatoidChromophobeTumorPatientsFactors associated with clinical trial participation for patients with renal cell carcinoma
Shinder B, Kim S, Srivastava A, Patel H, Jang T, Mayer T, Saraiya B, Ghodoussipour S, Singer E. Factors associated with clinical trial participation for patients with renal cell carcinoma. Urologic Oncology Seminars And Original Investigations 2023, 41: 208.e1-208.e8. PMID: 36868881, PMCID: PMC10106382, DOI: 10.1016/j.urolonc.2023.01.022.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCell carcinomaClinical trial participationClinical trialsOverall survivalClinical stageTrial patientsTrial participantsCharlson-Deyo comorbidity scoreAssociated with trial participationCompare overall survivalNational Cancer DatabaseLog-rank testClinical trial patientsPatient sociodemographic factorsAssociated with clinical trial participationMedian OSSuperior OSCancer DatabaseOncology clinical trialsSurvival outcomesMale patientsCase-control designPatient cohortControl cohort
2022
Renal Cell Carcinoma with Cardiac Metastases: A Case Report and Review of the Literature
Cahill E, Tabakin A, Shinder B, Bramwit M, Saraiya B, Xu X, Salazar C, Zhou Z, Singer E. Renal Cell Carcinoma with Cardiac Metastases: A Case Report and Review of the Literature. Journal Of Kidney Cancer And VHL 2022, 9: 32-38. PMID: 36118793, PMCID: PMC9431006, DOI: 10.15586/jkcvhl.v9i2.229.Peer-Reviewed Case Reports and Technical NotesRenal Cell Carcinoma with Testicular Metastases: A Case Report and Review of the Literature
Yoshitake S, Shinder B, Dazen K, Smith C, Mayer T, Sadimin E, Singer E. Renal Cell Carcinoma with Testicular Metastases: A Case Report and Review of the Literature. Journal Of Kidney Cancer And VHL 2022, 9: 22-26. PMID: 36118790, PMCID: PMC9430971, DOI: 10.15586/jkcvhl.v9i2.212.Peer-Reviewed Case Reports and Technical NotesFactors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma
Patel HV, Kim S, Srivastava A, Shinder BM, Sterling J, Saraiya B, Mayer TM, Ghodoussipour S, Jang TL, Singer EA. Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2022, 20: 296-296.e9. PMID: 35105510, PMCID: PMC9149103, DOI: 10.1016/j.clgc.2022.01.001.Peer-Reviewed Original ResearchConceptsStage IV RCCMetastatic renal cell carcinomaNational Cancer DatabasePalliative interventionsRenal cell carcinomaMetastatic RCCClinical factorsCell carcinomaMultivariable logistic regression modelComprehensive cancer programsQuality of lifeLogistic regression modelsSarcomatoid histologyAdvanced malignanciesOverall cohortHigher education statusOncologic careInsurance statusCancer DatabaseCancer programsEarly initiationIntervention utilizationTreatment-specific mannerPatientsPI use
2021
EDITORIAL COMMENT.
Srivastava A, Shinder B, Singer EA. EDITORIAL COMMENT. Urology 2021, 158: 115. PMID: 34895625, DOI: 10.1016/j.urology.2021.04.076.Commentaries, Editorials and LettersFactors Associated with Accurate Staging of Stage I and II Testicular Nonseminomatous Germ Cell Tumors (nsgct)
Patel H, Srivastava A, Shinder B, Kim I, Singer E, Ghodoussipour S, Jang T. Factors Associated with Accurate Staging of Stage I and II Testicular Nonseminomatous Germ Cell Tumors (nsgct). Journal Of The American College Of Surgeons 2021, 233: e230. DOI: 10.1016/j.jamcollsurg.2021.08.622.Peer-Reviewed Original ResearchMP19-08 DISPARITIES IN CLINICAL TRIAL PARTICIPATION FOR PATIENTS WITH RENAL CELL CARCINOMA AND PROSTATE CANCER
Shinder B, Kim S, Patel H, Mayer T, Saraiya B, Jang T, Kim I, Singer E. MP19-08 DISPARITIES IN CLINICAL TRIAL PARTICIPATION FOR PATIENTS WITH RENAL CELL CARCINOMA AND PROSTATE CANCER. Journal Of Urology 2021, 206: e330-e330. DOI: 10.1097/ju.0000000000002004.08.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Brian Shinder, MD, is a urologic oncologist who treats kidney, prostate, and bladder cancer.
Dr. Shinder says he was drawn to urology because of its variety, both in terms of conditions he treats and the types of procedures he performs. “It’s rewarding in that we can treat people and, in some cases, cure them of their disease, but also restore their function so that they can live better lives,” he says.
For most urologic diseases, surgery can be done either with a minimally invasive approach or through traditional, open surgery. “Both options have their place in treatment; it’s a matter of figuring out what is best for each patient based on their outcome and lifestyle goals,” Dr. Shinder says. “I make sure patients understand their options and help them decide the best way to move forward with their treatment.”
It's also an exciting time for the field, Dr. Shinder notes. “Urology has been at the forefront of robotic surgery. And the field continues to push boundaries regarding what can be done with robotic surgery,” he says. “There are also other, newer platforms and technologies to treat various diseases, including kidney stones and enlarged prostates. Urology has also been at the forefront of using genetics and different molecular markers to help diagnose conditions and decide the best treatment for patients.”
Clinical Specialties
Fact Sheets
Prostate Cancer
Learn More on Yale MedicineKidney Cancer
Learn More on Yale Medicine